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Abstract: The amyloid-β peptide (Aβ) has been associated with Alzheimer’s disease (AD) for decades. The original amy-
loid cascade hypothesis declared that the insoluble extracellular plaques were responsible for Aβ toxicity. Later, this hy-
pothesis has been updated and soluble intracellular Aβ forms and their effects within the cell have come into focus. Mito-
chondrial dysfunction plays an important role in the pathophysiology of AD. Aβ was detected inside mitochondria and 
several mitochondrial proteins were found to interact directly with Aβ. Such interactions can affect a protein’s function 
and cause damage to the mitochondria and finally to the whole cell. This review summarizes the current knowledge of mi-
tochondrial proteins directly interacting with Aβ and discusses their significance for the development of therapeutics in 
the treatment of AD. 
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INTRODUCTION 
Alzheimer’s disease (AD) is the most common cause of 
senile dementia and about 20 million people worldwide cur-
rently suffer from this devastating illness, with the number 
continuing to steadily rise due to an aging population [1]. 
Despite years of intensive research, the pathogenic mecha-
nisms of AD are still not fully understood and consequently 
an effective treatment is yet to be developed. AD is charac-
terized by the progressive decline of cognitive function and 
memory caused by the extensive death of neurons, which 
starts in the entorhinal cortex and hippocampus and proceeds 
to other parts of the brain cortex and subcortical grey matter. 
The main pathological hallmarks found in affected parts of 
the AD brain are represented by extracellular amyloid-β (Aβ) 
deposits also called senile plaques, intracellular deposits of 
phosphorylated tau-protein called neurofibrillary tangles and 
diffuse loss of neurons [2, 3]. 
Although the aetiology of AD is still unknown, a build-up 
of Aβ is considered to play an important role in disease pro-
gression. Aβ peptide is generated from APP (amyloid precur-
sor protein) via its sequential cleavage by β-secretase and γ -
secretase. This action takes place at several intracellular 
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sites, including within Golgi apparatus, endoplasmic reticu-
lum (ER), endosomal-lysosomal systems, and multivesicular 
bodies. Mutations in either APP or in the presenilin genes 
have been linked to familial, early onset forms of AD. How-
ever, these early onset cases represent only a small minority 
of AD patients (∼5%), whereas the vast majority of AD 
cases have developed sporadically [4, 5]. The original amy-
loid cascade hypothesis defined by Hardy et al. in 1992, pro-
posed that insoluble extracellular plaques were responsible 
for the majority of Aβ toxicity. This hypothesis has since 
been refined, as recent data indicates that soluble intracellu-
lar oligomers are now responsible for the majority of Aβ 
induced toxic effects [6-9]. 
A link between mitochondrial dysfunction and AD has 
long been suggested to exist. Mitochondria are central to 
many proceses including: cellular energetic metabolism, 
regulation of intracellular Ca2+ levels, the regulation of cell 
death and they are also the main source of reactive oxygen 
species (ROS). All these functions are found to be disturbed 
in AD, as well as in the presence of increased intracellular 
concentrations of Aβ in different in vitro and in vivo studies. 
These findings are summarized in recent review articles, 
therefore suggesting that Aβ is responsible for the induction 
of mitochondrial dysfunction typically observed in AD (Fig. 
1) [10-12]. 
Although Aβ is known to be present in mitochondria, its 
precise location within this compartment is a contentious 
issue. In most studies Aβ was found associated with the in-
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ner mitochondrial membrane (IMM) and not in the mito-
chondrial matrix, which is in contrast with findings that Aβ 
interacts with several proteins residing in the mitochondrial 
matrix. This discrepancy can be explained by the rapid Aβ 
degradation occurring in the matrix by mitochondrial prote-
ases (e.g. PreP or IDE) [13-15]. 
 
Fig. (1). Possible mitotoxic mechanisms induced by β-amyloid in 
AD. Reproduced with permission, from Tillement et al. Mitochon-
drion 2011, 11, 13-21 [10]. © Elsevier. 
Also the origin of mitochondrial Aβ is still a matter of 
debate. There is experimental evidence for both local pro-
duction (described later in the mitochondrial γ-secretase sec-
tion of this review) and direct import either from ER or from 
cytosol. The strongest evidence supports the hypothesis that 
Aβ can be transported into the mitochondria from the cytosol 
via mitochondrial TOM/TIM (translocase of the outer mem-
brane/ translocase of the inner membrane) protein-import 
machinery. In accordance with this theory, TOM40 complex 
was shown to transport Aβ across the outer mitochondrial 
membrane (OMM). However, the mechanistic details of how 
Aβ gains access to the different mitochondrial sub-
compartments are currently unestablished, since there are 
several pathways for protein translocation across (TIM23 
complex;) and into the IMM (TIM23 or TIM22 complexes). 
Another theory assumes mitochondria-associated membranes 
(MAMs) of the ER to be responsible for the import of Aβ 
from this compartment. MAMs are a physical connection 
between the ER membrane and the mitochondrial outer 
membrane, where lipids and membrane proteins are thought 
to be exchanged directly between the organelles (Fig. 2) [13-
15]. 
The particular molecular mechanism, through which Aβ 
exerts its toxicity in mitochondria, has not yet been deter-
mined. However, several mitochondrial proteins were ascer-
tained to, or are thought to, directly interact with Aβ. Such 
interactions could lead to the disruption of their physiologi-
cal functions and consequential mitochondrial dysfunction 
finally resulting in the development or progression of AD. In 
this article, we bring together an overview of proteins that 
have been suggested to directly interact with Aβ. We discuss 
their implications for AD pathogenesis and the potential of 
their pharmacological targeting with regards to therapeutics 
for AD. For each of these proteins we have also tried to pre-
sent validated compounds that may be useful in AD treat-
ment. In terms of druggability, the AD targeted compounds 
should be designed to fulfil the criteria of being able to cross 
the blood-brain barrier (BBB), therefore at the end of each 
chapter the reader can find a table of calculated physical-
chemical properties (ACDLabs PhysChemSuite 12.0 [16]) 
for the presented compounds, compared with optimal proper-
ties for CNS targeted drugs according to the updated Lipin-
ski rule of five [17]. 
AMYLOID-BINDING ALCOHOL DEHYDROGENASE 
(ABAD) 
Amyloid-binding alcohol dehydrogenase (ABAD) is a 27 
kDa tetrameric, NAD-dependent oxidoreductase, member of 
the short chain dehydrogenase reductase (SDR) family, re-
siding in the mitochondrial matrix. ABAD is a multifunc-
tional enzyme catalysing the reduction of aldehydes and ke-
tones and oxidation of alcohols and as such it is known to act 
on a broad range of structurally diverse substrates and con-
sequently to participate in several metabolic pathways. Its 
main physiological function is its involvement in the third 
step of β -oxidation of fatty acids with short branched side 
chains. ABAD’s ability to utilise the ketone body 
β-hydroxybutyrate makes ABAD play an important role for 
the cell’s capacity to overcome periods of metabolic stress. 
The enzyme is also required in isoleucine catabolism. Fur-
thermore, a role in sex steroid and neurosteroid metabolism 
was also attributed to ABAD due to its 3α- and 17 β-
hydroxysteroid dehydrogenase activities [14, 18, 19]. 
ABAD is currently the most characterized Aβ-binding in-
tracellular protein and the interaction between ABAD and 
Aβ (both 1-40 and 1-42) has been demonstrated by many 
different approaches. The finding that ABAD’s expression 
levels are increased in the brains of AD patients further sup-
ports the connection between ABAD and AD. Aβ was shown 
to bind to ABAD on a region of the enzyme called loop D, 
changing its conformation and preventing the binding of the 
enzyme’s cofactor NAD+ in a competitive manner, thus in-
hibiting enzyme activity at micromolar concentrations (Fig. 
3). This binding also occurs in nanomolar levels, which is 
also indicative of the cytotoxic effect of Aβ. Furthermore, 
only catalytically active ABAD was shown to enhance Aβ 
toxicity, as cell culture studies found that the expression of a 
catalytically inactive form of ABAD in the presence of Aβ 
does not enhance cytotoxicity. Similar conclusions were also 
made for in vivo studies with transgenic mice. Although, the 
precise mechanism of ABAD-mediated Aβ toxicity is cur-
rently unknown, it is independent of enzyme’s inactivation. 
Combining the evidence from these studies reveals that the 
binding of Aβ to ABAD triggers a cascade of events leading 
to mitochondrial dysfunction a characteristic of AD [14, 18, 
19]. 
Lustbader et al. established that the ABAD-Aβ interac-
tion is a suitable therapeutical target by using the ABAD-
decoy peptide (ABAD-DP)[20]. ABAD-DP mimics the bind-
ing region of ABAD for Aβ (loop D). In vitro studies found 
ABAD-DP bound to Aβ1-40 and Aβ1-42 making it unable to 
interact with ABAD. When tested in cell culture experi-
ments, ABAD-DP ameliorated the mitochondrial impairment
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Fig. (2). APP and Aβ inside the cell. During protein synthesis, the APP is targeted to the ER and transported to the plasma membrane by ve-
sicular transport through the Golgi apparatus. Amyloidogenic processing of APP by the β- and γ-secretases at the plasma membrane produces 
the Aβ. This cleavage has also been found to take place prior to exocytosis in the trans-Golgi network (1). Aβ can aggregate extracellularly 
forming extracellular plaques, which are one of the hallmarks of AD (2). APP undergoes endocytosis and is normally recycled to the plasma 
membrane via recycling endosomes. Aβ peptides can also enter the cell by endocytosis, but can also be produced from APP by β - and γ-
secretase cleavage in endosomes (3). Aβ can also compromise the integrity of endosomes and secretory vesicles and can be found in the cyto-
sol, probably due to leakage out of these compartments (4). Aβ can be imported into the mitochondria via the TOM/TIM mitochondrial im-
port machinery. Owing to its chimaeric targeting sequence, APP can also be transported to mitochondria where it gets stuck within TOM and 
TIM proteins, disturbing mitochondrial protein import (5). Mitochondrial peptidases PreP and IDE are capable of degrading Aβ in the mito-
chondrial matrix (6). Reproduced with permission, from Muirhead et al., 2010, Biochemical Journal, 426(3), 255-270. © The Biochemical 
Society [14]. 
caused by Aβ and its cytotoxicity. Transgenic AD mice 
treated with ABAD-DP displayed improved cognitive func-
tion [20-22]. In an in vitro screen searching for small mole-
cule inhibitors of the ABAD-Aβ interaction, frentizole (an 
FDA approved immunosuppressant; Fig. 4; Table 1) was 
identified. Consequently, several analogue series of fren-
tizole compounds have been generated and two of these 
compounds (4a, 4b; Fig. 4; Table 1) were tested (in vitro) for 
their ability to ameliorate Aβ1-42 cytotoxicity with promis-
ing results [23, 24]. 
As ABAD activity is necessary for enhancing Aβ toxic-
ity, ABAD inhibitors could also be used as a therapeutic for 
AD. However, some side effects may be encountered by 
the use of such treatments as this may potentially cause the 
inhibition of the enzyme’s physiological functions. Cur-
rently only two specific small molecule ABAD inhibitors 
are known; AG18051 (Fig. 4; Table 1) an irreversible in-
hibitor creating a covalent adduct with the cofactor NAD+ 
inside the active site. AG18051 has been shown in several 
studies to decrease Aβ1-42 toxicity at the cellular level [25, 
26]. The second compound, named RM-532-46 (Fig. 4; 
Table 1), is a reversible ABAD inhibitor with a steroid 
structure [27]. 
CYCLOPHILIN D (CypD) 
Cyclophilin D (CypD), also termed peptidyl-prolyl cis-
trans isomerase F, is a 22 kDa protein residing in the mito-
chondrial matrix. CypD has several enzymatic functions in-
cluding roles in protein folding (cis-trans isomerisation of 
peptide bonds) and as a chaperone protein. However, it was 
later shown that CypD (and other cyclophilins) do not play 
an essential role in protein folding and it was proposed that 
each cyclophilin could regulate a restricted number of unique 
partner proteins. CypD was found to play a role in the regu-
lation of the mitochondrial permeability transition (mPT) and 
within the regulation of ATP synthase activity. Recent stud-
ies suggest that these two effects may be closely related [28-
30]. 
Mitochondrial permeability transition could be defined as 
the collapse of the chemiosmotic gradient across the IMM 
mediated by the opening of a large conductance pore called 
the mitochondrial permeability transition pore (mPTP), 
whose molecular composition remains unknown. The mPTP 
plays a key role in cell death and has proved to be a viable 
target for therapeutic intervention in a variety of diseases 
including neurodegeneration. CypD is a key regulator and 
component of mPTP. In times of cellular stress CypD 
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Fig. (3). Crystal structure of Aβ-bound human ABAD. A) A ribbon diagram with labeled secondary structures and the loop D (LD), LE, and 
LF loops. Helices are shown in green, β strands are shown in blue, and loops are shown in pink. Disordered regions are shown by dotted lines. 
B) Superposition of Aβ-bound human ABAD (pink) and rat ABAD in complex with NAD (blue). The LD of 3α-hydroxysteroid dehydro-
genase is shown in yellow to demonstrate that LD of ABAD contains a unique insertion absent in all other SDR family members. NAD is 
shown as a stick model with gray for carbon atoms, red for oxygen atoms, blue for nitrogen atoms, and yellow for phosphate atoms. The pro-
posed Aβ-binding loop is indicated. C) Superposition of the active sites of Aβ-bound human ABAD (pink) and rat ABAD (blue), showing 
distortion of the NAD binding site and the catalytic triad S155, K162, and Y168. Colors are the same as in B). D) A section of the crystal packing 
interactions, showing the large solvent channels. Each ABAD molecule is shown in a different color. The ordered ends of the LD, residues 94 
and 114, are marked as red and blue balls, respectively, and the hypothetical loops are shown in pink as dotted lines. Reproduced with per-
mission, from Lustbader et al. Science 2004, 304, 448-452 [20]. © The American Association for the Advancement of Science. 
translocates from the mitochondrial matrix to the IMM, 
where it interacts with components of the mPTP inducing 
pore opening [28-30]. CypD mediated mPTP opening was 
shown to be involved in AD pathophysiology by several 
different approaches both in vitro and in vivo. Moreover, Aβ 
was shown to induce mPTP opening and CypD defi-
ciency/inhibition was shown to reduce Aβ cytotoxicity. A 
more detailed account of these findings are presented in sev-
eral recent review articles [30-33]. 
CypD was also found to directly interact with Aβ show-
ing a higher affinity to oligomeric rather than to monomeric 
Aβ and to Aβ1-42 over Aβ1-40 [34]. The binding between 
CypD and Aβ was also studied using computational simula-
tions [35]. It was suggested that CypD mediated Aβ toxicity 
could be driven in two ways, indirectly by elevated ROS 
levels caused by Aβ accumulation inside mitochondria and 
directly, specifically via the CypD-Aβ interaction [31]. 
CypD inhibitors were shown to suppress mPTP opening 
and therefore represent potential drugs against diseases, in 
which increased mPT and cell death takes place including 
AD [28]. Cyclic undecapeptide cyclosporine A (CsA; Fig. 5; 
Table 2), which is used clinically as an immunosuppressant, 
is the best-known CypD inhibitor. CsA lacks clinical signifi-
cance because of its immunosuppressive effect mediated by 
calcineurin inhibition and its inability to pass through the 
blood-brain barrier. However, several non-immunosuppres- 
sive CsA derivatives have been developed, including alis-
porivir (Debio 025, UNIL-025), NIM 811 and SCY-635 [36, 
37]. Macrolide sanglifehrin A (SfA; Fig. 5; Table 2) and 
other sanglifehrins present another class of CypD inhibitors 
with similar mechanisms of action to CsA. Although SfA 
does not inhibit calcineurin activity, it still exerts an im-
munosuppressive effect by an unknown mechanism dif-
ferent to CsA [38]. Interestingly, synthetic SfA analogues 
devoid of immunosuppressive properties and with improved 
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Fig. (4). Structure of selected ABAD modulators. 
 
Table 1. Predicted Physical-chemical Properties of Selected ABAD Modulators Compared to Optimal Properties for CNS Targeted 
Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
Frentizole	   299.35	   5/2	   91	   3.2	   2.5	   7.0	  
4a	   452.42	   9/2	   154	   4.0	   4.0	   9.3	  
4b	   394.38	   7/2	   128	   3.0	   3.0	   9.4	  
AG18051	   367.47	   6/1	   97	   2.0	   1.9	   8.8	  
RM-532-46	   480.68	   5/1	   53	   4.4	   4.1	   14.7	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Fig. (5). Structure of selected CypD inhibitors. 
pharmacokinetics were prepared [38, 39]. Recently a cyclic 
decapeptide antamanide (Fig. 5; Table 2) was identified as a 
CypD inhibitor. Unfortunately, it seems to have the same 
therapeutical disadvantages as the previously described CsA 
[40]. 
Collectively, currently available CypD inhibitors lack 
clinical significance in AD, because they are large molecules 
with high molecular weights, resulting in poor cell perme-
ability and an inability to cross the blood-brain barrier [36, 
37]. Moreover, these inhibitors are not specific for CypD 
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over the other cyclophilin subtypes. Hence, there is a need 
for developing new small molecules that can overcome any 
potential side effect and specificity issues. In search for 
small molecule CypD inhibitors, Gue et al. synthesized a 
series of novel quinoxaline analogues. Remarkably, one of 
these compounds (GW5; Fig. 5; Table 2) exhibited some 
selectivity for binding CypD over CypA [41]. Other small 
molecule inhibitors could be found from the results of crys-
tallographic studies, which identified the molecular differ-
ences between CypD and other cyclophilins [42]. 
ADENINE NUCLEOTIDE TRANSLOCASE (ANT) 
Adenine nucleotide translocase (ANT), a mitochondrial 
protein that facilitates the exchange of ADP and ATP across 
the IMM, plays an essential role in cellular energy metabo-
lism. Human ANT presents four isoforms (ANT1-4), each 
with a specific expression depending on the nature of the 
tissue, cell type, developmental stage and status of cell pro-
liferation. Thus, ANT1 is specific to muscle and brain tis-
sues, ANT2 occurs mainly in proliferative undifferentiated 
cells, ANT3 is expressed ubiquitously and ANT4 is found in 
germ cells. ANT1 and ANT3 export the ATP produced by 
oxidative phosphorylation (OxPhos) from mitochondria into 
the cytosol while importing ADP. In contrast, ANT2 imports 
glycolytically produced ATP into the mitochondria, when 
OxPhos activity is impaired [43]. ANT1 and ANT3 seem to 
act proapoptotically, possibly due to their involvement in 
mPT, whereas ANT2 and ANT4 seem to act anti-
apoptotically [44]. 
Early studies suggested that ANT is a critical component 
of mPTP, along with voltage-dependent anion channel 
(VDAC) in the OMM and CypD in the matrix. In contrast 
with this theory, Kokoszka et al. inactivated the two ANT 
isoforms (ANT1 and ANT3) relevant for mPT in mice and 
they still detected the opening of mPTP triggered by Ca2+, 
suggesting that ANT is not an essential part of the mPTP. 
However, ANT still seems to play a role in the regulation of 
mPTP since more Ca2+ was required to activate the mPTP 
and ANT ligands no longer regulated the mPT in this mouse 
model [45]. Recent studies defined the composition of mPTP 
as the dimer of the F0F1-ATP synthase that is regulated by 
CypD. In view of the fact that adenine nucleotides are the 
substrates of the ATP synthase, ANT may contribute to mPT 
regulation by affecting nucleotide levels in the matrix, where 
the F1-ATPase sector of the ATP synthase is located [46]. 
The connection between AD and ANT is mostly based on 
its involvement in mPTP formation and cell death. A direct 
interaction between ANT and Aβ was firstly predicted in a 
computational simulation and later described using an in 
vitro assay. In that study Aβ1-42 fibrils were shown to in-
hibit ANT1 mediated ADP/ATP exchange in a non-
competitive manner [35, 47]. However, the consequences of 
such an interaction remain elusive as well as characterising 
the role of ANT in mPT and cell death. 
Due to its regulatory role in mPTP opening, ANT (or 
more precisely isoforms 1 and 3) presents a potential phar-
macological target for the treatment of AD and other dis-
eases, in which pronounced cell death takes place. Interest-
ingly, ANT inhibitors can have different effects on mPT and 
cell death regulation. Carboxylatractyloside (CAT) and 
bongkrekic acid (BKA; Fig. 6; Table 3), both inhibitors of 
ANT, were shown to exert opposite effects on mPTP open-
ing. CAT binds to the intermembrane space (IMS) side of 
ANT, from the cytosolic surface and induces the termed “c” 
conformation of ANT and sensitizes pore opening by Ca2+. 
Conversely, BKA binds to the matrix side of ANT, promot-
ing the “m” conformation and inhibiting pore opening. The 
transition between CAT and BKA conformations is sug-
gested to be the structural switch involved in ADP/ATP 
transport [46, 48]. Based upon the above mentioned data, 
only ANT inhibitors with effects similar to BKA can be con-
sidered for AD treatment. 
Several synthetic analogues which focused on the struc-
ture of BKA (Fig. 6; Table 3) were designed and synthesized 
in an attempt to find new mPT inhibitors [49, 50]. Nelfinavir 
(Fig. 6; Table 3), an inhibitor of HIV protease, was also 
shown to inhibit mPT perhaps via an interaction with ANT 
[51, 52]. Additionally, N-ethylmaleiimide and nitro-linoleate 
(LNO2; Fig. 6; Table 3) were found to modify ANT’s critical 
cysteine residues leading to the inhibition of both ANT and 
mPT [53, 54]. 
VOLTAGE-DEPENDENT ANION CHANNEL (VDAC) 
Voltage-dependent anion channel (VDAC) is a small (31 
kDa) highly conserved protein residing primarily in the outer 
mitochondrial membrane of all eukaryotes. Furthermore, 
VDAC can also be found inside the plasma membrane and 
ER. VDAC’s principal function as a membrane channel in 
the OMM is to facilitate and regulate the flow of ions, nu-
Table 2. Predicted Physical-chemical Properties of Selected CypD Inhibitors Compared to Optimal Properties for CNS Targeted 
Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
CsA	   1202.61	   23/5	   279	   2.8	   2.8	   13.3	  
SfA	   1090.39	   18/9	   273	   6.3	   6.3	   9.9	  
GW5	   374.39	   7/1	   84	   3.6	   3.6	   12.7	  
antamanide	   1147.37	   20/6	   256	   4.0	   4.0	   13.4	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cleotides and other metabolites between the cytosol and the 
mitochondrial intermembrane space. Therefore, it plays an 
important part in the regulation of energetic metabolism, 
Ca2+ signalling and cell death [55, 56]. VDAC functions can 
be affected by posttranslational modifications occurred via 
oxidation, phosphorylation, carbonylation or nitration. Sub-
sequently, several VDAC binding partners have also been 
identified, e.g. members of Bcl-2 family, hexokinase and 
many others. Hence, from these findings VDAC seems to be 
involved in many different signalling pathways inside the 
cell [55, 57]. 
Three eukaryotic VDAC isoforms, encoded by three 
separate genes, VDAC1, VDAC2 and VDAC3, have been 
identified in mitochondria. The specific role of each iso-
form remains unclear, although evidence indicates that the 
three isoforms may serve different physiologic functions in 
different tissues. It seems apparent that VDAC1 has a pro-
apoptotic function, VDAC2 an anti-apoptotic function and 
VDAC3 has no influence on apoptosis. As a consequence 
of this VDAC1 and 2 are involved in the control of ROS. It 
should also be mentioned, that before the three isoforms 
were discovered, the majority of studies conducted on 
VDAC were in fact conducted on the VDAC1 isoform [58]. 
The connection between VDAC and AD was originally 
based upon the assumption, that VDAC is a structural com-
ponent of the mPTP. This theory has recently been chal-
lenged, although VDAC still seems to participate in the regu-
lation of cell death and apoptosis in AD [59, 60]. Elevated 
VDAC1 levels were found in AD brain samples and VDAC1 
levels were also shown to increase in an age-dependent man-
ner [55, 60]. However, its specific contribution to the devel-
opment of AD is unknown. 
The direct interaction of VDAC1 with monomeric and 
oligomeric Aβ as well as full length APP and phosphorylated 
tau was described by Manczak and Reddy. In this work they 
suggest that such interactions may in turn block mitochon-
drial pores and interrupt crosstalk between mitochondria and 
cytosol leading to mitochondrial dysfunction or in the rup-
ture of the OMM. In relation to the interaction between Aβ 
and VDAC1, the C-terminus of the Aβ peptide motif 
‘GSNKG’ (at positions 25-29) has been proposed to interact 
with the N-terminal motif of VDAC1 ‘GYGFG’ [61]. 
However, there are some other theories considering the 
role of VDAC in AD or cell death. Thinnes suggested, that 
the interaction of Aβ and VDAC1 (within the plasma mem-
brane), and its consequent opening could present the basic 
model for an extrinsic apoptotic pathway and the cause of 
AD [56]. Moreover, VDAC1 found localized in this region, 
was suggested to mediate the neuroprotective effect of estra-
diol against Aβ induced toxicity [62]. Other theories con-
sider the formation of a mitochondrial pore based upon 
VDAC oligomerization or VDAC hetero-oligomerization 
together with Bax, which could lead to the release of cyto-
chrome c and cell death [57]. 
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Fig. (6). Structure of selected ANT inhibitors. 
 
Table 3. Predicted Physical-chemical Properties of Selected ANT Inhibitors Compared to Optimal Properties for CNS Targeted 
Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
BKA	   486.6	   7/3	   121	   4.6	   -1.1	   4.2	  
nelfinavir	   552.77	   6/4	   124	   7.0	   7.0	   9.6	  
LNO2	   325.44	   5/1	   83	   4.1	   1.5	   4.8	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Because of its ambiguous role in AD pathophysiology, 
exploitating VDAC as a drug target for AD therapeutics is a 
contentious issue. However, there are some drugs that have 
been shown to exert cytoprotective effects via an interaction 
with VDAC, namely olesoxime (TRO-19622), a cholesterol-
like neuroprotectant for the potential treatment of amyotro-
phic lateral sclerosis (ALS), or fluoxetin, a clinically used 
antidepressant (Fig. 7; Table 4) [63, 64]. 
N
HO
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H N
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olesoxime fluoxetin  
Fig. (7). Structure of selected VDAC interacting compounds. 
ELECTRON TRANSPORT CHAIN (ETC) 
The mitochondrial ETC (electron transport chain) is 
composed of five enzyme complexes embedded in the inner 
membrane of the mitochondria. The reduced equivalents of 
NADH and FADH2 derived from the oxidation of carbohy-
drates and fatty acids flow from Complex I through Complex 
IV via a series of oxidation-reduction events. The energy, 
released during the process, charges the inner mitochondrial 
membrane and drives ATPase (Complex V) to synthesize 
ATP from ADP and inorganic phosphate [65]. 
The impairment of the respiratory chain can lead to de-
creased electron transfer efficiency, reduced ATP produc-
tion, and increased reactive oxygen species (ROS) produc-
tion by the mitochondria, which are typical hallmarks of AD 
[10]. The most reported defect in the ETC, in connection 
with AD, is the decreased activity of Complex IV. Changes 
in activity of the remaining ETC complexes were also re-
ported, but the data is inconsistent, varying from inhibition 
to activation. Aβ was reported to directly interact with Com-
plex I, IV and V, which in all cases lead to their inhibition. 
Generally, enzyme complexes of ETC do not appear to be 
feasible drug targets for the treatment of neurodegenerative 
disorders. 
COMPLEX I 
In Complex I (NADH: ubiquinone oxidoreductase; EC 
1.6.5.3), two electrons are removed from NADH and trans-
ferred to a lipid-soluble carrier, ubiquinone. The reduced 
product, ubiquinol, freely diffuses within the membrane and 
Complex I translocates four protons across the membrane, 
thus producing a proton gradient. Complex I is one of the 
main sites at which premature electron leakage to oxygen 
occurs, thus making it one of the main sites of superoxide 
production [66]. 
The direct interaction between Aβ and Complex I was 
described in two independent studies and the C-terminal se-
quence of the ND3 subunit was identified as the binding site 
for Aβ1-42 [65, 67]. Aβ was shown to inhibit Complex I 
activity and to increase Complex I-dependent production of 
ROS, which in turn lead to mitochondrial dysfunction. How-
ever, even when a mitochondrial defect can be attributed to 
Complex I, it is hard to determine whether the effects ob-
served arise from a loss of Complex I activity, an increase in 
its ROS production, or both [65].  
Interestingly, MPTP and rotenone, classical Complex I 
inhibitors, are used for creating a pharmacological model of 
Parkinson’s disease (PD), which further supports the role of 
Complex I in neurodegeneration [68]. The natural compound 
bilobalide (Fig. 9; Table 5) and its two synthetic analogues 
were shown to possess protective effects towards the ETC 
[69]. Their studies revealed that they were able to prevent the 
inhibition of complex I by amobarbital [69], unfortunately 
the precise mechanism of action is unknown, so we can only 
speculate whether this effect is mediated via a direct interac-
tion with Complex I. 
COMPLEX IV 
In Complex IV (cytochrome c oxidase; EC 1.9.3.1), four 
electrons are removed from four molecules of cytochrome c 
and transferred to molecular oxygen, producing two mole-
cules of water. At the same time, four protons are removed 
from the mitochondrial matrix (although only two are trans-
located across the membrane), contributing to the proton 
gradient [66]. 
Decreased activity of Complex IV was reported in AD 
patient brain samples [70, 71], transgenic animal models [72, 
73] and in vitro studies using Aβ [74, 75]. Recently, a direct 
interaction of Aβ1-42 with cytochrome c oxidase subunit 1 
was also reported (Fig. 8) [76]. Another study showed that 
the apparent Km of cytochrome c oxidase for reduced cyto-
chrome c was raised, indicating that Aβ 1-42 and Aβ25-35 
may act as an inhibitors for cytochrome c binding [75]. 
In regard to AD treatment, caprospinol (Fig. 9; Table 5), 
a naturally occurring, stable steroid molecule devoid of ster-
oid activity demonstrates neuroprotective properties, which, 
Table 4. Predicted Physical-chemical Properties of Selected VDAC Interacting Compounds Compared to Optimal Properties for 
CNS Targeted Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
olesoxime	   399.65	   2/1	   33	   9.7	   9.7	   12.3	  
fluoxetin	   309.33	   2/1	   21	   3.9	   1.4	   NA*	  
* Not available. 
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amongst its other roles, is attributed to affecting complex IV 
and V of respiratory chain [77, 78]. 
O
O
O
O
caprospinol
O
O
O
O
O
O
H
HOH
OH
bilobalide  
Fig. (9). Structure of selected neuroprotectants that affecting ETC. 
ATP SYNTHASE (COMPLEX V) 
The electrochemical gradient created by proton pumps 
(Complex I, III and IV) is used by the F0F1 ATP synthase 
complex to generate ATP via oxidative phosphorylation. The 
F0 component of ATP synthase acts as an ion channel that 
provides a proton flux into the mitochondrial matrix. This 
reflux releases free energy, which is used to drive ATP syn-
thesis catalyzed by the F1 component of the complex [66]. 
This complex was also found on the cell surface, where it is 
capable of synthesizing ATP extracellularly [79, 80]. 
The direct binding of Aβ1-40 to the α-subunit (a member 
of the F1 component) of cell surface ATP synthase and its 
consequent inhibition has been previously described [80, 81]. 
Furthermore, it was proposed that the inhibition of cell sur-
face ATP synthase by Aβ may consequently affect synaptic 
plasticity leading to memory deficits in AD [80-82]. Whether 
this interaction also takes place in mitochondria has not yet 
been confirmed. 
α-KETOGLUTARATE DEHYDROGENASE COM-
PLEX (KGDHC) 
α-ketoglutarate dehydrogenase complex (KGDHC) cata-
lyzes the oxidative decarboxylation of α -ketoglutarate to 
succinyl-CoA, a key step in the tricarboxylic acid cycle. Its 
function is therefore important for energy metabolism, pro-
duction of reducing equivalents (NADH), glutamate neuro-
transmission and protein synthesis. KGDHC consists of three 
protein subunits E1k (α-ketoglutarate dehydrogenase, E.C. 
1.2.4.2), E2k (dihydrolipoamide succinyltransferase, EC 
2.3.1.61) and E3 (dihydrolipoyl dehydrogenase, EC 1.8.1.4) 
and is located within the IMM [83, 84]. 
Diminished KGDHC activity occurs in brain samples of 
AD patients and it appears that decreased KGDHC activity 
in the AD brain is part of a neurodegenerative cascade [83, 
85]. Oxidative stress is most often mentioned as a link be-
tween KGDHC deficiency and AD, because KGDHC is par-
ticularly vulnerable to free radicals and elevated ROS levels 
[83, 86]. On the other hand, there is also evidence suggesting 
that KGDHC could be inhibited by a direct interaction with 
Aβ. Aβ25-35 was shown to inhibit KGDHC activity in a 
dose dependent manner for both purified enzyme and iso-
lated mitochondria [75, 87]. However no binding studies, 
which would confirm the direct interaction have been re-
ported to date. 
PYRUVATE DEHYDROGENASE COMPLEX (PDHC) 
Pyruvate dehydrogenase complex (PDHC) is distributed 
heterogeneously within the mitochondrial matrix, where it 
catalyzes the irreversible oxidative decarboxylation of pyru-
vate to acetyl-CoA. This reaction links the glycolysis in the 
cytoplasm to the oxidative phosphorylation in the mitochon-
dria and is rate-limiting (under aerobic conditions) for the 
oxidative removal of glucose and pyruvate [88, 89]. PDHC is 
composed of multiple copies of three catalytic, one binding 
and two regulatory components, namely PDH (pyruvate de-
hydrogenase, EC 1.2.4.1), E2 (dihydrolipoamide acetyltrans-
ferase, EC 2.3.1.12) and E3 (dihydrolipoamide dehydro-
genase, EC 1.8.1.4) plus E3BP (E3-binding protein), PDHK 
(PDH kinase) and PDP (PDH phosphatase) [88]. 
 
Fig. (8). Molecular Dynamics complex of Aβ 1-42 (blue) and cytochrome c oxidase subunit 1 (gold). Upper panel: nine pairs of carbons 
(spheres) interacting through van der Waals forces forming hydrophobic contacts between both peptides are showed. Insets show the hydro-
gen-bond (green dots) between E11-Y54 (left); the salt bridge (red dots) of H13 and H14 with D51 (left) and the salt bridge between E22-
H61 (right). Reproduced from Hernandez-Zimbron et al. PloS One 2012, 7, e42344 [76]. © Hernandez-Zimbron et al. 
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Postmortem analyses of brains from patients with AD 
have repeatedly demonstrated significant decreases in the 
activity of the PDHC and similar results were obtained using 
an AD animal model [85, 90]. The mechanism behind PDHC 
deficiency in AD has not yet been clarified, although several 
hypotheses exist including enzyme oxidation due to in-
creased oxidative stress [91] or increased phosphorylation by 
TPKI/GSK-3β [92, 93]. 
Another possibility is that PDHC could be inhibited by a 
direct interaction with Aβ. Aβ25-35 was shown to inhibit 
PDHC activity in a dose dependent manner for both purified 
enzyme and isolated mitochondria [75, 87]. Similarly to 
KGDHC, no binding studies that would further confirm this 
hypothesis have been reported as yet. 
Activation of PDHC is possible through the inhibition of 
its regulatory kinase PDHK. Synthetic PDHK inhibitors (e.g. 
sodium dichloroacetate or AZD7545; Fig. 10; Table 6) were 
developed for the treatment of several diseases such as dia-
betes, heart disease and cancer. Though their application for 
the treatment of neurodegenerative diseases has also been 
suggested, no such studies have been performed as yet [89, 
94, 95]. 
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Fig. (10). Structure of selected PDHK inhibitors. 
CREATINE KINASE (CK) 
Creatine kinase (CK; EC 2.7.3.2) catalyzes the reversi-
ble conversion of creatine and ATP to phosphocreatine and 
ADP. Therefore, CK is an important mediator of cellular 
homeostasis since it can create a pool of phosphocreatine 
for temporal and spatial ATP buffering. Four CK isoforms 
are distinguished based on their tissue expression (muscle 
or brain) and subcellular distribution (cytosolic or mito-
chondrial). Therefore, there are two tissue specific mito-
chondrial CK (mtCK) isoenzymes termed as sarcomeric 
mtCK, which are found in striated muscle, and ubiquitous 
mtCK, which is found in most other tissue types including 
neural tissue. Both mtCKs are located in the mitochondrial 
IMS [96, 97]. 
Changes in creatine metabolism, CK activity and CK ex-
pression were observed in AD [98-101]. CK activity in 
brains of AD patients was decreased whereas elevated CK 
levels were found in AD mouse model. The diminished CK 
activity may be related to oxidative stress, considering that 
CK is very sensitive to oxidative insult. This was supported 
by proteomic studies, which found CK to be significantly 
oxidatively modified in AD brains [98-101]. 
The direct interaction of CK with Aβ is a contentious is-
sue as there is only one published study reporting indirect 
evidence [102]. In this study, it was shown that Aβ25-35 
inhibits CK activity in a dose-dependent manner. The pro-
posed mechanism suggested that Aβ derived radicals react 
non-specifically with the enzyme to oxidize it or to create 
covalent CK-Aβ adducts [102]. Interestingly, ubiquitous 
mtCK was found to directly interact with APP. This interac-
tion stabilizes the CK pre-protein, which could play a protec-
tive role against cell stress and axonal injury [103]. 
γ-SECRETASE 
γ-secretase is a protein complex of approximately 500 
kDa, made up of enzymatically-active PS1 or PS2, nicastrin 
(NCT), presenilin enhancer 2 (PEN2), and anterior pharynx-
defective phenotype (APH-1) [104]. It is most often men-
tioned in connection with AD, because γ -secretase together 
with β -secretase (BACE) gives rise to Aβ by the sequential 
cleavage of APP. In addition to APP cleavage, the γ -
secretase complex is responsible for the processing of Notch, 
E-cadherin, ErbB4, and p75NTR. γ-secretase activity and 
components of the γ -secretase complex have been found in 
the ER, the Golgi apparatus, the plasma membrane, the en-
dosomal/lysosomal system and recently, the mitochondria 
[105, 106]. Mutations in PS1 are responsible for more than 
50% of familial AD cases. These PS1 mutations tend to shift 
the γ -secretase cleavage specificity of C99 to increase the 
production of the toxic Aβ1-42 over Aβ1-40. PS2 mutations 
are less abundant, but also lead to increased Aβ1-42 produc-
tion [106]. 
PS1 was found to be located in mitochondria and prefer-
entially in the IMM by Ankarcrona and Hultenby and later 
the whole functional γ-secretase complex was established to 
be present inside mitochondria by Hansson et al. [104, 107]. 
From these findings the question of whether Aβ could be 
produced locally in mitochondria arose. Although, APP is 
known to be imported to mitochondria, it was shown to be 
trapped inside the mitochondrial importers TOM40 and 
Table 5. Predicted Physical-chemical Properties of Selected Neuroprotectants Affecting ETC Compared to Optimal Properties for 
CNS Targeted Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
caprospinol	   512.76	   4/0	   45	   9.6	   9.6	   NA*	  
bilobalide	   326.30	   8/2	   119	   4.5	   4.5	   11.7	  
* Not available. 
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TIM23 in an orientation which is incompatible for cleavage 
by mitochondrial γ-secretase and therefore the possibility of 
local Aβ production seemed to be unlikely [108]. Later, an 
interaction between mitochondrial γ -secretase and 
HtrA2/Omi protease was described (the role of HtrA2 in AD 
is described in a later section of this review) and also within 
this study, amyloid precursor protein intracellular domain 
(AICD) was found to be produced from APP inside the mi-
tochondria potentially due to the cooperation of γ -secretase 
and HtrA2 [109]. 
In 2011 Pavlov et al. described for the first time, that C83 
(product of APP cleavage by α -secretase) is present in the 
OMM and can be cleaved by the mitochondrial γ-secretase to 
produce AICD which also remains attached to the IMS side 
of the OMM. However, the proposed mechanism of γ -
secretase action would lead to the release of Aβ into the cy-
toplasm [110]. Interestingly, Devi and Ohno found C99 (a 
product of APP cleavage by BACE) and APP to be located 
in the mitoplast [111]. But it is unclear, whether there is a 
functional γ -secretase in IMM capable of C99 cleavage. 
Therefore the possibility of local Aβ production in mito-
chondria remains obscure as well as the physiological func-
tion of mitochondrial γ-secretase. 
Recently, HIG1 (hypoxia-inducible gene 1, domain 
member 1A), a novel regulator of γ -secretase activity, has 
been described [112]. HIG1 was found to be localized on 
mitochondrial membrane where it interacts with proteins of 
the γ -secretase complex. HIG1 overexpression was able to 
decrease mitochondrial γ -secretase activity and Aβ intracel-
lular production and consequently to reduce hypoxia-induced 
mitochondrial dysfunction. Conversely, HIG1-knockdown 
also resulted in mitochondrial dysfunction [112]. Based on 
these results, mitochondrial γ-secretase seems to be a poten-
tial drug target for AD therapy. 
In an effort to find a therapy for AD, many γ -secretase 
inhibitors/modulators have been discovered during the past 
20 years. Initial compounds were non-selective γ -secretase 
inhibitors (GSIs). These compounds actually proved to be 
toxic, because they inhibited not only APP processing, but 
also the processing of other γ -secretase substrates, particu-
larly Notch 1. Therefore, currently developed GSIs are de-
signed as APP selective or “Notch sparing”. Another class of 
potential AD therapeutics targeting γ -secretase are γ -
secretase modulators (GSMs). These compounds do not in-
hibit the overall enzyme activity but shift γ-secretase activity 
towards the increased production of the less toxic shorter Aβ 
species and decreased production of the toxic longer Aβ spe-
cies, principally Aβ1-42. A large amount of work has been 
done in the field of GSIs/GSMs and further information can 
be found in several other recent review articles [113, 114]. 
NITRIC OXIDE SYNTHASE (NOS) 
Nitric oxide synthase (NOS; EC 1.14.13.39) is presented 
by a family of three NO˙ synthase enzymes, neuronal NOS 
(nNOS, NOS1), inducible NOS (iNOS, NOS2), and endothe-
lial NOS (eNOS, NOS3). Each NOS isoform is encoded by a 
unique gene. NOS catalyzes the degradation of L-arginine to 
equal amounts of NO˙ and L-citrulline, and requires Ca2+-
calmodulin for its activity [115]. 
NO˙ exerts a broad spectrum of functions in several sys-
tems, including the cardiovascular system, PNS, CNS and 
immune system. These functions are mediated through the 
reactions of NO˙ with targets that include hemoproteins, 
thiols and superoxide anions. Mitochondria possess several 
such targets and they are also major cellular source of super-
oxide anion. Therefore, mitochondria contribute to many 
biological functions exerted by NO˙ [115]. 
The presence of NOS inside mitochondria had not been 
conclusively validated until recently. All three NOS isoforms 
have been previously proposed to be located within mito-
chondria of different cells [116]. Furthermore, the existence 
of a novel isoform, specific to mitochondria, cannot be ex-
cluded [117, 118]. On the contrary, some studies suggest that 
NOS is not present in mitochondria at all [119]. Another 
theory is that mtNOS is tissue specific and/or that in differ-
ent tissues the function of mtNOS could be exerted by a dif-
ferent NOS isoform. However, recent research conducted in 
this field indicated that most often nNOSα are identical to 
mtNOS [116]. mtNOS was found to be localized at the ma-
trix side of the IMM, where it interacts with complex I and 
IV of the mitochondrial respiratory chain [120] and the role 
of mtNOS in the regulation of mitochondrial respiration and 
mPT was proposed [116, 117, 120]. 
The data regarding the role of NO˙ and changes in NOS 
expression levels in AD are quite inconsistent, differing from 
protective [121, 122] to deleterious [123, 124] and from de-
creased [125] to elevated [123, 124]. A possible explanation 
for this discrepancy could be explained by the finding that 
physiological NO˙ levels are neuroprotective whereas in-
creased levels are cytotoxic [126]. 
Several studies suggested a connection between NOS ac-
tivity and the development of AD, whereby the activity of 
the iNOS and eNOS isoforms were found to be protective in 
Table 6. Predicted Physical-chemical Properties of Selected PDHK Inhibitors Compared to Optimal Properties for CNS Targeted 
Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
AZD7545	   464.84	   7/2	   112	   0.6	   0.6	   10.3	  
dichloroacetate	   128.94	   2/1	   37	   0.7	   -3.1	   1.4	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AD as their gene deletion led to an enhancement of Aβ tox-
icity and an exacerbation of AD symptoms [122, 127, 128]. 
Conversely, nNOS was found to be toxic in AD, where the 
deleterious effect could potentially be mediated by an nNOS 
interaction with Cdk5 and Aβ [129]. Therefore, it is not sur-
prising that inhibitors of NOS (particularly nNOS) are con-
sidered as potential AD treatment [130, 131]. However, it 
should be mentioned that there are also studies bringing con-
trary evidence for the role of particular NOS isoforms in AD 
and there is still a lot of questions to be answered. 
Recently, the direct interaction of Aβ with nNOS was de-
scribed by Padayachee et al. [132]. Different Aβ species 
were found to inhibit nNOS activity in a non-competitive 
manner and hydrophobic regions of Aβ (pentapeptide patch 
and three glycine zipper regions) were found to be crucial for 
this interaction. Moreover, nNOS was found to act as a cata-
lyst of Aβ fibrillogenesis and aggregation [133]. Whether 
this interaction is universal for other NOS isoforms or 
mtNOS is yet to be determined. 
As far as we are aware, there have been no published 
studies depicting mtNOS in AD pathology. However, 
mtNOS has been reported to be involved in the pathophysi-
ology of ALS, another neurodegenerative disease, where 
mtNOS activity was observed to decrease in an age-
dependent manner. This finding could play a part in the 
developement of age-related disease including AD [134, 
135]. 
Many NOS inhibitors are known, both non-specific (e.g. 
L-NAME; Fig. 11; Table 7) and isoform specific (e.g. 
nNOS-specific 7-nitroindazole and iNOS-specific amino-
guanidine; Fig. 11; Table 7). However, we can still only 
speculate, which type of pharmacological modulation of 
mtNOS or other NOS isoforms would be beneficial for AD 
treatment [130, 131]. 
PEPTIDYLARGININE DEIMINASES (PAD) 
Peptidylarginine deiminases (PAD; EC 3.5.3.15), also 
called as protein-arginine deiminases, are a family of cal-
cium dependent enzymes that mediate post-translational 
modifications of proteins’ on arginine residues by deimina-
tion or demethylimination producing citrulline. There are 
five PAD family members (PAD1-4 and 6), each with a 
unique tissue distribution and functional roles [136]. PAD2 
and PAD4 have been previously connected with AD patho-
physiology as they can be both found in CNS. Therefore we 
will only further describe these two isoenzymes in this re-
view. 
PAD2 is widely expressed in multiple tissues, including 
secretory glands, brain, uterus, spleen, pancreas and skeletal 
muscle and is mainly a cytoplasmic protein, but a fraction of 
PAD2 may become nuclear [136]. Recent evidence suggests 
that PAD2 is also found in mitochondria. Moreover, levels 
of PAD2 expression and levels of citrullinated proteins in 
mitochondria were found increased in mice infected with 
scrapie, a fatal neurodegenerative prion disease [137]. How-
ever, there are no studies reported regarding the role of mito-
chondrial PAD2 in AD. PAD4 is expressed mainly in white 
blood cells including granulocytes and monocytes under 
physiological conditions and in a wide range of tumors in 
various tissues. Recently, PAD4 activity was also detected in 
neurons. Inside the cell, PAD4 is primarily located in the 
nucleus [136, 138]. 
Increased activity of PAD2 and elevated levels of citrul-
linated proteins were found in AD brain samples, however, 
no PAD2 activity was found in healthy controls. Therefore, it 
is assumed in a healthy individual that PAD2 normally re-
mains inactive, but becomes activated and citrullinates cellu-
lar proteins only when the intracellular calcium balance is 
disrupted during neurodegenerative processes [139]. Moreo-
ver, PAD2 expression increases during life, which supports 
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Fig. (11). Structure of selected NOS inhibitors. 
 
Table 7. Predicted Physical-chemical Properties of Selected NOS Inhibitors Compared to Optimal Properties for CNS Targeted 
Drugs 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
L-NAME	   233.23	   9/5	   146	   -1.3	   -3.4	   5.0	  
7-nitroindazole	   163.13	   5/1	   75	   1.4	   1.4	   10.0	  
aminoguanidine	   74.09	   4/6	   88	   -1.5	   -2.6	   NA*	  
* Not available. 
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its possible role in development of age-related diseases 
[140]. The toxic mechanism of citrullinated proteins in AD 
has not yet been elucidated. However, several theories exist 
for instance the autoimmunity against citrullinated proteins 
or negative impact on enolase activity [138, 141]. Therefore, 
inhibitors of PAD2/PAD4 were suggested as potential AD 
treatment [138, 141]. 
Different Aβ species were shown to bind to PAD2, inhibit-
ing its activity. The nature of the interaction is very similar to 
a previously described mechanism for another arginine me-
tabolising enzyme, nNOS (see NOS section). Similarly, PAD2 
was found to catalyze Aβ fibrillogenesis and aggregation, al-
though at a slower rate in comparison to nNOS [133, 142]. 
Many non-selective PAD inhibitors (e.g. Cl-amidine; Fig. 
12; Table 8) or isoform selective (especially towards PAD4; 
e.g. TDFA, streptonigrin; Fig. 12; Table 8) [143, 144] have 
been discovered, however, a specific inhibitor of PAD2 has 
not yet been identified. 
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Fig. (12). Structure of selected PAD inhibitors. 
CU/ZN SUPEROXIDE DISMUTASE (SOD1) 
Cu/Zn superoxide dismutase (SOD1; EC 1.15.1.1) is a 
ubiquitously expressed homodimeric metalloenzyme acting 
as a free radical scavenger. It catalyzes the dismutation of 
superoxide radicals to hydrogen peroxide and molecular 
oxygen. SOD1 is predominantly localized in the cytosol, but 
it can also be found in other cellular compartments including 
the nucleus, ER, lysosomes and mitochondria. In mitochon-
dria, SOD1 is concentrated in the IMS, but it is also found in 
the matrix and on the OMM [145-147]. 
Some mutations in the SOD1 gene lead in the develop-
ment of a familial form of the neurodegenerative disease 
ALS, which shares some similarities with AD and PD [148]. 
In regard to AD, impaired SOD1 function is connected with 
increased oxidative stress, which is one of AD hallmarks. 
Impaired function of SOD1 was also observed in AD pa-
tients and the animal models. Choi et al. found that SOD1 is 
heavily oxidized in AD and PD brains by carbonylation and 
that the important Cys146 thiol group is irreversibly oxidized 
to sulfonic acid. They also found that the total level of SOD1 
is significantly increased in both AD and PD. Finally, they 
observed and characterized SOD1 aggregates in AD and PD 
brains concluding that oxidative damage to SOD1 and its 
subsequent aggregation may contribute to the neurodegen-
eration associated with AD and PD [149]. This is in agree-
ment with other study showing that Aβ accelerates SOD1 
aggregation [150]. Later, Murakami et al. showed that SOD1 
deficiency in an APP-overexpressing AD mouse model ac-
celerated Aβ oligomerization and memory impairment, when 
compared to control AD mice. However, unlike Choi et al., 
they found that levels of SOD1 were significantly decreased 
in AD patients rather than non-AD age-matched individuals 
[151]. Therefore, changes in SOD1 expression and activity 
in regard to AD remain obscure as several studies showed 
inconsistent results [149, 151, 152]. In several studies in-
creased SOD1 activity was shown to protects against Aβ 
toxicity [153-155]. However and in contrast with these stud-
ies, Harris-Cerruti et al. concluded that increased expression 
of SOD1 has deleterious effects in APP-overexpressing mice 
[156]. 
In 2009 a direct interaction between SOD1 and various 
species of Aβ and its consequent inhibition was observed for 
the first time by Yoon et al. and later their results were con-
firmed by Oyatsi and Whiteley. The glycine zipper region of 
Aβ was identified as being responsible for SOD1 binding 
and inhibition, particularly the pentapeptide Aβ29-33 [157, 
158]. Alternatively, Aβ was suggested to inhibit SOD1 activ-
ity through the sequestration of Cu2+ cations, since Cu2+ is 
fundamental for the redox reaction involving the dismutation 
of superoxide [159]. The activators of SOD1 might be bene-
ficial in this case for AD treatment, but to date there is no 
published literature data on specific SOD1 activators. 
CATALASE 
Catalase (EC 1.11.1.6) is a common enzyme found in 
nearly all living organisms exposed to oxygen. It catalyzes 
Table 8. Predicted Physical-chemical Properties of Selected PAD Inhibitors Compared to Optimal Properties for CNS Targeted 
Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
Cl-amidine	   310.78	   6/5	   108	   0.8	   -1.1	   13.3	  
TDFA	   448.45	   13/9	   224	   -2.7	   -5.2	   4.2	  
streptonigrin	   506.46	   12/6	   197	   0.1	   -3.2	   3.6	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the decomposition of two hydrogen peroxide molecules to 
water and molecular oxygen. Continuous and effective deg-
radation of H2O2 is essential for aerobic life for two main 
reasons, the removal of excessive H2O2 and the strict regula-
tion of its concentration in signaling pathways. Catalase can 
be found predominantly in peroxisomes and in small 
amounts within the cytosol [160]. Little is known about cata-
lase localized in the mitochondrial matrix, however it was 
first discovered in rat heart mitochondria and later catalase 
was found in rat liver mitochondria [161, 162]. Still, it re-
mains to be established whether there are other tissues con-
taining mitochondrial catalase and what is its physiological 
function [163]. 
Increased ROS levels have been connected with AD for a 
long time, either as a cause or as a consequence. Therefore, it 
is no surprise, that catalase, an enzyme with antioxidant 
properties, is considered to be implicated in AD pathology 
[164, 165]. In mice, the overexpression of mitochondria-
targeted catalase was shown to ameliorate Aβ toxicity and 
contrary, the inhibition of catalase was shown to enhance Aβ 
toxicity [166, 167]. 
Aβ was found to directly interact with catalase and to in-
hibit its enzymatic activity [168, 169]. Aminoacids 400-409 
of the human catalase protein were identified as binding site 
for the Aβ25-35 peptide. Catalase derived peptide (CAβBD) 
comprising these critical residues was shown to bind and 
scavenge Aβ, which consequently led to decreased Aβ bind-
ing to catalase and neuroprotection [170]. These findings are 
very similar to the ones obtained using ABAD-DP as de-
scribed in the ABAD section of this review. Interestingly, 
kisspeptin, a physiological peptide sharing some structural 
similarities with CAβBD, was shown to ameliorate Aβ toxic-
ity in the same way. This finding raises a question, whether 
kisspeptin plays a part in Aβ detoxification in vivo [171]. 
Moreover, small molecule inhibitors of catalase-Aβ in-
teraction have also been discovered (BTA-EG4 and BTA-
EG6; Fig. 13; Table 9). They were shown to significantly 
reduce the co-localization of Aβ and catalase inside the cell, 
protect catalase enzymatic function and reduce Aβ toxicity. 
However, these inhibitors are derivatives of the Aβ-binding 
dye thioflavin T and their effects are based on the interaction 
with Aβ and not with catalase. Therefore, they are able to 
prevent the interaction of Aβ with other binding partners 
(e.g. ABAD), which could also contribute to their cytopro-
tective properties [169, 172]. Conversely in another study, an 
inhibitor of the catalase-Aβ interaction (BTA-EG4) was 
shown to decrease some of the neuroprotective effects of 
catalase overexpression. A possible explanation for this ob-
servation is that catalase ameliorates Aβ toxicity via two 
independent ways, firstly it decreases elevated ROS levels 
and secondly that it acts as a scavenger of Aβ and the latter 
function is blocked by BTA-EG4 [173]. However, the latest 
study demonstrated that BTA-EG4 produces an age-specific 
improvement in synaptic density and cognitive function in an 
AD mouse model, when administered daily for two weeks 
and an associated change in dendritic spine density with in-
creased Ras activity [174]. Additionally, polyphenol phloro-
glucinol (Fig. 13; Table 9) was found to increase catalase 
activity and expression, which could be applicable for an AD 
treatment. However, the mechanism for catalase activation 
has not yet been elucidated [175, 176]. 
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Fig. (13). Structure of selected catalase acting agents. 
DYNAMIN-RELATED PROTEIN 1 (DRP1) 
The balance between fission and fussion is important for 
maintaining normal mitochondrial size, shape, and distribu-
tion, and to supply energy to high-demand sites, such as 
nerve terminals. Aβ causes changes to the expression and 
distribution of mitochondrial fussion and fission proteins 
leading to impaired mitochondrial dynamics and neuronal 
dysfunction [177]. 
Dynamin-related protein 1 (Drp1), also referred to as dy-
namin-like protein 1 (DLP1), is one of the dynamin-related 
GTPase, enzymes regulating mitochondrial fussion and fis-
sion. Most of Drp1 is localized to the cytoplasm, but a small 
part is localized in the OMM, where it punctuates and pro-
motes mitochondrial fission [178]. Drp1 also plays a part in 
mitochondrial fragmentation, mitochondrial outer membrane 
permeability (MOMP) and cytochrome c release during 
apoptosis [179]. However, it remains to be established, 
whether its role in apoptosis is mediated by the same signal 
pathway as mitochondrial fission, or whether this function is 
mediated through an independent mechanism [180]. 
Table 9. Predicted Physical-chemical Properties of Selected Catalase Acting Agents Compared to Optimal Properties for CNS 
Targeted Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
BTA-EG4	   416.53	   6/2	   101	   3.0	   3.0	   14.4	  
BTA-EG6	   504.64	   8/2	   120	   2.5	   2.5	   14.4	  
phloroglucinol	   126.11	   3/3	   61	   0.1	   -0.1	   9.1	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Both monomeric and oligomeric forms of Aβ were iden-
tified to interact with Drp1 using co-immunoprecipitation 
and immunofluorescence analyses, where such an interaction 
could lead to disruption of mitochondrial dynamics, shape 
and size observed in AD [178]. 
P110 is a selective peptide inhibitor of Drp1 GTPase ac-
tivity preventing its interaction with Fis1 (binding site for 
Drp1 on OMM) and consequently inhibiting the transloca-
tion of Drp1 to the mitochondria. P110 was originally de-
signed as an inhibitor of the protein-protein interaction (PPI) 
between Drp1 and Fis1. The peptide comprises residues of 
Drp1, which were supposed to be involved in PPI of Drp1 
with Fis1, but suprisingly it was shown to specifically inhibit 
Drp1 GTPase activity. It also prevents the binding of Drp1 to 
Fis1, but it is not known whether this is caused by the same 
interaction of P110 with Drp1 or whether P110 also binds 
Fis1 as proposed during its design. P110 was demonstrated 
to have a cytoprotective effect under stress conditions in 
cultured neuronal cells, exhibiting protection from mito-
chondrial dysfunction, excessive fission and cell death [181]. 
Dynasore (Fig. 14; Table 10) is a small molecule inhibi-
tor of the GTPase activity of dynamin-1, dynamin-2 and 
Drp1, which was discovered in a chemical screen for inhibi-
tors of dynamin-1 GTPase activity. Dynasore inhibits GTP 
hydrolysis in these enzymes in non-competetive manner by 
binding to their GTPase domain. Dynasore was found to 
decrease cell damage in heart reperfusion injury through 
maintaining mitochondrial morphology and ATP production 
[182]. 
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Fig. (14). Structure of selected Drp1 inhibitors. 
Mdivi-1 (Fig. 14; Table 10) was the first selective Drp1 
inhibitor. The mechanism of mdivi-1 inhibition is distinct in 
comparison to the more general Drp1 inhibitor dynasore, 
whereby mdivi-1 binds to an allosteric site that does not ex-
clusively act through the GTPase domain. Upon binding, 
mdivi-1 creates or stabilizes a conformational form of unas-
sembled, likely dimeric Drp1 that can bind GTP, but at a 
significantly lower affinity. This mdivi-1-dependent confor-
mational state is not able to assemble into a Drp1 fila-
ment/spiral, indicating that mdivi-1 inhibits mitochondrial 
fission by blocking the Drp1 polymerization. Mdivi-1 was 
also found to exert a cytoprotective effect in brain or heart 
reperfusion injury and to ameliorate Aβ induced neurotoxic-
ity. These cytoprotective effects are probably mediated via 
inhibiting mitochondrial outer membrane permeabilization 
and cytochrome c release [183, 184]. 
GLYCERALDEHYDE-3-PHOSPHATE DEHYDRO-
GENASE (GAPDH) 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 
EC. 1.2.1.12) is a soluble 148 kDa homotetrameric, intracel-
lular protein that exerts multiple functions. Originally known 
for its role in glucose metabolism GAPDH was recently 
found to participate in many other cellular processes such as 
DNA repair, tRNA export, membrane fusion and transport, 
cytoskeletal dynamics, Ca2+ release or cell death and it also 
possesses kinase/phosphotransferase activity. Moreover, 
GAPDH binds numerous endogenous small molecules (e.g. 
TNF-α ribozymes, glutathione, p53, and nitric oxide) and 
was found to interact with disease-associated proteins like 
huntingtin, Aβ and APP. In addition to the cytoplasm where 
the majority of GAPDH is located under basal conditions, 
GAPDH is also found in other cell fractions such as nuclear, 
mitochondrial, and the small vesicular fractions [185, 186]. 
Although GAPDH was found in mitochondrial subcellular 
fractions, it remains to be elucidated, whether it is capable of 
entering the mitochondrial lumen or if it is just absorbed 
through the OMM. 
There is strong evidence that GAPDH participates in AD 
development and progression. The recently performed meta-
analyses of genetic association studies found 13 genes that 
play a significant role in AD and among them GAPDH 
[187]. On the biochemical level, increased expression to-
gether with decreased activity of GAPDH was observed in 
AD and denaturated GAPDH was found to be incorporated 
in Aβ and tau aggregates [188]. In connection with AD, an-
other interesting protein-protein interaction was observed 
between GAPDH and VDAC, a protein residing in the OMM 
and participating in mPTP opening (described earlier in the 
review). GAPDH overexpression was found to cause mito-
chondrial swelling and cell death probably due to its interac-
tion with VDAC [189]. 
The direct interaction between GAPDH and Aβ1-40 and 
Aβ1-42, both monomeric and fibrillary, was observed in 
several studies [190-192], although in one particular study 
this interaction was observed only for a denaturated form of 
GAPDH and soluble Aβ [188]. However, the consequences 
of this interaction on the enzyme’s functions remain unclear. 
Table 10. Predicted Physical-chemical Properties of Selected Drp1 Inhibitors Compared to Optimal Properties for CNS Targeted 
Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
dynasore	   322.31	   6/4	   102	   3.3	   3.2	   8.8	  
mdivi-1	   353.22	   4/1	   74	   4.5	   4.5	   9.9	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Deprenyl (Fig. 15; Table 11) and other irreversible 
monoamine oxidase B (MAO B) inhibitors comprising a 
propargylamine moiety were found to possess neuroprotec-
tive properties that are independent of MAO B inhibition. 
Studies on one such molecule, CGP 3466 (Fig. 15; Ta-
ble 11), a neuroprotective propargylamine that does not in-
hibit MAO B, identified GAPDH as the target structure for 
its neuroprotective effects. CGP 3466 was shown to interact 
with the binding site of its cofactor, NAD+, which resulted in 
apoptosis inhibition [193-195]. A similar mechanism of ac-
tion was also proposed for the aliphatic propargylamines 
(e.g. R-2HMP; Fig. 15; Table 11) with anti-apoptotic activity 
[196]. Accordingly, isatin (Fig. 15; Table 11), an endoge-
nous reversible MAO B inhibitor, was identified to bind to 
GAPDH without significant influence on its activity, where 
It binds to the same site as deprenyl and it was also proposed 
to possess similar neuroprotective properties [197]. 
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Fig. (15). Structure of selected GAPDH neuroprotectants. 
HIGH TEMPERATURE REQUIREMENT PROTEASE 
A2 (HTRA2) 
High temperature requirement protease A2 (HtrA2), also 
called Omi or PARK13, is a mitochondrial serine protease 
with chaperone activity residing in the mitochondrial IMS. A 
fraction of the endogenous HtrA2/Omi pool has been also 
detected in the nucleus and associated with the cytosolic side 
of ER [198, 199]. Its main physiological function is pro-
posed to be the maintainance of mitochondrial function by 
handling misfolded proteins in the IMS. In addition, HtrA2 
has been implicated as a pro-apoptotic factor upon release 
into the cytosol during the cell death cascade [199, 200]. 
However, according to genetic studies, the normal physio-
logical function of HtrA2 appears to be anti-apoptotic where 
decreased HtrA2 activity leads to a neurodegenerative dis-
ease phenotype [201]. Therefore, HtrA2 seems to have two 
distinct roles, under normal physiological conditions it is 
required within the mitochondria for the maintenance of mi-
tochondrial homeostasis, and under apoptotic conditions 
where it is released from the mitochondria and has a pro-
apoptotic role [202]. 
To date, studies of HtrA2 have predominantly focused on 
PD. The first association of HtrA2 with AD was a study in 
which HtrA2 was identified as a presenilin-1-interacting 
factor in a yeast two-hybrid screen [203]. The c-terminus of 
presenilin-1 was later shown to interact with the PDZ do-
main of HtrA2, which led to the stimulation of HtrA2 prote-
ase activity [204]. Recently, HtrA2 was shown to to modu-
late mitochondrial γ -secretase activity and to interact with 
presenilin in an active γ-secretase complex located within the 
mitochondria [109]. Another connection to AD is corrobo-
rated by the observation that APP is a direct substrate for 
HtrA2 and it was suggested that HtrA2 prevents the accumu-
lation of APP in mitochondria through APP cleavage by its 
serine protease activity [205]. Westerlund et al. observed 
changes to the expression and activity of HtrA2 in AD pa-
tient brains, where the total levels of processed HtrA2 were 
decreased, although the levels of mRNA were unchanged 
and the proteolytic activity was even increased [206]. 
HtrA2 directly interacts with Aβ through its PDZ domain 
which was described for the first time by Park et al. in 2004 
[207]. Another study elucidated that HtrA2 preferentially 
binds to oligomeric Aβ1-42 in comparison to monomeric Aβ 
or APP [201]. Additionally, HtrA2 was shown to prevent Aβ 
aggregation and also to be capable of disaggregating oli-
gomeric Aβ, which consequently led to a decrease in Aβ 
toxicity [201]. Furthermore, the interaction with Aβ inhibited 
the pro-apoptotic activity of HtrA2 [201]. Kooistra et al. 
have found that HtrA2 is capable of Aβ1-42 cleavage, which 
could contribute to the inhibition of its aggregation. How-
ever, they also observed that HtrA2 retains its anti-
aggregation properties even when devoid of either its prote-
olytic activity or its PDZ domain [208]. In contrast, another 
study revealed that the overexpression of HtrA2 decreases 
Aβ1-40/ Aβ1-42 generation, although HtrA2 was not found 
to be directly involved in Aβ production or its cleavage 
[209]. 
Combining these findings it becomes apparent that HtrA2 
appears to be involved in AD pathophysiology, although the 
Table 11. Predicted Physical-chemical Properties of Selected GAPDH Neuroprotectants Compared to Optimal Properties for CNS 
Targeted Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
deprenyl	   187.28	   1/0	   3	   2.7	   2.3	   NA*	  
R-2HMP	   167.29	   1/0	   3	   3.4	   2.9	   NA*	  
CGP 3466	   275.34	   2/0	   12	   3.5	   3.5	   NA*	  
isatin	   147.13	   3/1	   46	   1.4	   1.4	   10.3	  
* Not available. 
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precise connection between HtrA2 and AD remains unclear 
and it is not yet known, what type of HtrA2 pharmacological 
modulation would be beneficial in regards to an AD treat-
ment. The inhibition of HtrA2 enzymatic activity was shown 
to suppress apoptotic cell death. Hence, HtrA2 inhibition 
could present a novel therapeutical strategy for the treatment 
of many diseases where apoptosis is one of the key patho-
logical components [210, 211]. Ucf-101 (Fig. 16; Table 12) 
is currently the only known specific HtrA2 inhibitor, where 
it acts in a reversible and competitive manner [212]. Other 
compounds described to inhibit HtrA2 activity are generally 
non-specific inhibitors of serine proteases (e.g. phen-
ylmethanesulfonyl fluoride or diisopropylfluorophosphate) 
[203]. 
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Fig. (16). Structure of ucf-101. 
Several proteins and peptides have been shown to acti-
vate HtrA2 protease activity through binding to its PDZ do-
main [200, 204, 213, 214]. This finding presents potential 
background for the development of specific activators acting 
in a similar manner. In addition, a novel HtrA2 allosteric 
binding site called selective binding pocket (SBP) was dis-
covered recently and the binding of substrate peptides in 
SBP was shown to increase HtrA2 activity [215]. 
AMYLOID-β  DEGRADING ENZYMES 
Two enzymes, presequence protease (PreP) and insulin-
degrading enzyme (IDE), were found to be capable of Aβ 
clearance inside mitochondria (and possibly HtrA2; see ear-
lier described HtrA2 chapter) [213]. These enzymes are both 
members of pitrilysin oligopeptidase family with inverted 
zinc-binding motif also called inverzincin family [216]. 
PRESEQUENCE PROTEASE (PreP) 
Presequence protease (PreP), also termed metalloendo-
protease 1 or metallopeptidase 1 [217, 218], was firstly iden-
tified and characterized as a mitochondrial matrix and chlo-
roplast stroma metalloendopeptidase in Arabidopsis 
thaliana, but this enzyme can also be found in all species 
except among the Archea. It is responsible for the degrada-
tion of mitochondrial presequences (targeting peptides) that 
are generated after mitochondrial precursor protein import 
and processing. PreP has been shown to degrade not only the 
targeting peptides but also other unstructured peptides and 
the human variant of PreP was found to be responsible for 
Aβ1-40 and Aβ1-42 degradation inside the matrix of human 
brain mitochondria (Fig. 17) [219]. In an in situ study by 
Falkevall et al., it was found that the immuno-inactivation of 
PreP completly inhibits mitochondrial proteolytic activity 
against Aβ1-40 suggesting that PreP is the sole enzyme re-
sponsible for Aβ cleavage inside mitochondria [220] and the 
same conclusion was drawn in a later study using both im-
muno- and chemical PreP inactivation [221]. This finding is 
in contrast with the mitochondrial localization of another Aβ 
cleaving enzyme IDE (described later in this article). 
Decreased PreP activity was found in AD brains and in 
the brains of a transgenic mouse model for AD. However, 
PreP expression levels were not significantly changed sug-
gesting that the lower PreP activity was caused via its inacti-
vation [221], as PreP can be inactivated under oxidizing 
conditions. Firstly, it was concluded that this inactivation 
was caused by the formation of a disulfide bridge between 
the two close cysteine residues locking the enzyme in a 
closed (inactive) conformation. This was further supported 
by the finding that mutating one of the cysteine residues to a 
serine leads to the protection against oxidizing conditions 
[220]. However, another study attempting to reactivate the 
oxidatively inactivated PreP enzyme by pre-incubation with 
DTT (dithiothreitol; a reducing agent) revealed inconsistent 
results indicating that other factors, such as amino acid 
modification rather than disulphide bond formation may be 
responsible for PreP inactivation [221, 222]. These findings 
connect PreP to AD, because both, elevated ROS levels and 
PreP inactivation are observed in AD. 
Recently, small molecule PreP activators (3c, 4c; Fig. 18; 
Table 13) have been discovered and their capability to in-
crease Aβ degradation was evaluated in vitro. Such com-
pounds potentially present new therapeutics against AD 
[223]. 
INSULIN-DEGRADING ENZYME (IDE) 
Insulin-degrading enzyme (IDE, EC 3.4.24.56), also 
termed insulysin or insulinase, is a 110kDa widely expressed 
zinc metallopeptidase that has been shown to regulate both 
plasma insulin levels and cerebral Aβ in vivo. IDE is pre-
dominantly localized in the cytosol, with smaller amounts 
observed in peroxisomes, rough ER, plasma membranes and 
mitochondria depending on cell type. A secreted form of 
Table 12. Predicted Physical-chemical Properties of ucf-101 Compared to Optimal Properties for CNS Targeted Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
ucf-101	   493.53	   6/0	   125	   4.9	   4.9	   NA*	  
* Not available. 
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IDE is also present within extracellular compartments such 
as CSF. IDE has been shown to play a major role in the deg-
radation and clearance of insulin in vivo, however its expres-
sion in insulin-insensitive tissues suggests that IDE may ex-
ert other functions. Among insulin, IDE degrades a wide 
range of substrates that share a common amyloidogenic sec-
ondary protein structure e.g. amylin, insulin-like growth fac-
tors I and II and Aβ. Therefore, IDE likely plays a role in 
catabolic regulation, especially in preventing the formation 
of amyloid deposits by cleaving the component peptides 
(Fig. 19) [224-226]. IDE was also shown to possess chap-
eron like activity as Aβ was found to form a highly stable 
complex with IDE (in addition to also being IDE’s substrate) 
which consequently blocks its self-assembling into cytotoxic 
oligomers [227, 228]. 
 
Fig. (17). Structural homology model of hPreP with the Aβ12-17 
based on the three-dimensional structure of AtPreP. A) Structural 
model of hPreP with Aβ12-17 bound to the active site. B) Close-up 
of the active site with residues that differ in AtPreP shown in paren-
theses. Reproduced with permission, from Falkevall et al. J. Biol. 
Chem. 2006, 281, 29096-29104 [220]. © The American Society for 
Biochemistry and Molecular Biology. 
A mitochondrial isoform of IDE was identified in 2004 
by Leissring et al. This isoform is generated by IDE transla-
tion beginning at an alternative initiation codon, upstream of 
the canonical starting site, thus producing a novel protein 
targeted to the mitochondria [224]. Recently, the PGC-
1α/NRF-1 signaling pathway was shown to regulate the ex-
pression of mitochondrial IDE and consequently to modulate 
Aβ levels in mitochondria [229]. It was also proposed that 
inside mitochondria IDE could metabolize mitochondrial 
presequence [224]. However, it should be noted that the 
same functions are also executed by the related and mito-
chondrial enzyme PreP [220, 221]. 
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Fig. (18). Structure of selected PreP activators. 
In relation to AD, IDE activity was found to be decreased 
in brains of AD patients and negatively correlated with Aβ1-
40 and Aβ1-42 levels in brain [230, 231]. Furthermore, IDE 
expression and activity can be regulated by several signaling 
pathways that have been previously connected with AD de-
velopment, e.g. estradiol [232], norepinephrin [233], 
NOTCH [234], ApoE [235], PPARγ [236] or S-nitrosylation 
[237]. Meta-analysis performed by Zhang et al. suggested 
the association between IDE polymorphism and AD [238]. 
Interestingly, IDE also presents a possible link between type 
2 diabetes and AD as decreased IDE activity is a common 
feature in both diseases and people with type 2 diabetes are 
statistically more likely to develop AD [225, 231, 239]. 
IDE is an allosteric enzyme displaying sigmoidal sub-
strate consumption and possessing two different allosteric 
binding sites. The first one binds small peptide substrates 
(e.g. bradykinin, β -endorphin, some dynorphins, insulin B 
chain or somatostatin), which leads to enzyme activation. 
Interestingly, such activation of IDE is selective towards 
Aβ1-40 cleavage when compared to insulin. This finding 
suggested the possibility of developing small-molecule pep-
tide analogs that can serve to increase IDE activity towards 
Aβ cleavage in vivo, without affecting the IDE-dependent 
cleavage of insulin [240-243]. Accordingly, 10 small mole-
cule compounds were recently identified by virtual screening 
and four of them (D3, D4, D6, D10; Fig. 20; Table 14) were 
shown to be potent IDE activators [244]. The second allos-
teric site, called the anion binding site, is activated by poly-
anions such as ATP and triphosphate [243, 245, 246]. A high 
throughput screen was performed to detect compounds that 
interact with the ATP-binding domain leading to the discov-
ery of two small molecule activators (Ia1, Ia2; Fig. 20; Ta-
ble 14). Despite promising IDE activating properties, shown 
with the use of fluorescing substrates, these compounds do 
not enhance Aβ degradation if Aβ is present as the sole sub-
strate, but only if it is present in a mixture with shorter sub-
strate peptides [247]. Additionally, apomorphin (Fig. 20; 
Table 14) was also shown to induce IDE activity in an in 
vitro assay, however the mechanism of this activation is not 
yet known [248]. 
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Table 13. Predicted Physical-chemical Properties of Selected PreP Activators Compared to Optimal Properties for CNS Targeted 
Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
3c	   519.14	   7/2	   104	   5.0	   4.9	   8.2	  
4c	   706.18	   8/3	   113	   6.7	   6.6	   8.9	  
 
 
Fig. (19). Interactions between Aβ and IDE. Left panel: surface representation of IDE in complex with Aβ. IDE is depicted as transparent 
surface to allow visualization of the bound Aβ in the cavity. IDE-N and IDE-C domains are depicted as transparent blue and gray surfaces, 
respectively. The hinge region of IDE is depicted as yellow ribbon, and Aβ is depicted as sticks with carbon, nitrogen, and oxygen atoms 
colored yellow, blue, and red, respectively. Central panel: view of IDE-N after a rotation of -90 degree around the y axis separating IDE-N 
and IDE-C has been applied. Catalytic site and exosite are indicated by the catalytic zinc ion, depicted as magenta sphere, and by the green 
surface, respectively. Right panel: details of Aβ1-40 conformation bound to IDE (depicted as yellow sticks) superimposed to Aβ alone (de-
picted as transparent gray cartoon). Yellow dash lines show segments of IDE-bound Aβ1-40 not revealed in the electron density map. Black 
arrows show the position of the known cleavage sites of Aβ by IDE, according also to the sequence shown above. Reproduced with permis-
sion, from Malito et al. Cell. Mol. Life Sci. CMLS 2008, 65, 2574-2585 [216]. © Springer Science and Business Media. 
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Fig. (20). Structure of selected IDE activators. 
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Table 14. Predicted Physical-chemical Properties of Selected IDE Activators Compared to Optimal Properties for CNS Targeted 
Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
D3	   499.58	   8/1	   114	   2.2	   2.2	   13.9	  
D4	   427.47	   5/3	   77	   5.5	   5.5	   12.1	  
D6	   443.24	   8/0	   109	   5.4	   5.4	   NA*	  
D10	   448.43	   9/0	   109	   5.1	   5.1	   NA*	  
Ia1	   398.26	   6/0	   110	   3.2	   0.7	   3.9	  
Ia2	   370.83	   6/2	   74	   4.6	   4.6	   13.5	  
apomorphin	   267.32	   3/2	   44	   1.7	   1.2	   9.4	  
* Not available. 
HEAT SHOCK PROTEINS (Hsps) 
Heat shock proteins (Hsps) exert their function as mo-
lecular chaperones. Molecular chaperones are a family of 
proteins that facilitate and regulate proper protein folding. 
Whereby, molecular chaperones make sure that other pro-
teins arrive safely and are functional at their destination 
within the cell. They also ensure that proteins deemed to be 
‘ill-behaved’ or abnormal are destroyed [249-251]. 
Heat shock proteins can be divided into two different 
families based on size and function: classic Hsps such as 
Hsp100, Hsp90, Hsp70, Hsp60, and the small Hsps. Hsps 
with a molecular weight of 60 kDa or more possess an ATP-
binding site and are actively involved in the process of re-
folding misfolded proteins. Small Hsps, with a molecular 
weight of 40 kDa or less, lack this ATP-binding site and as-
sist the classic Hsps in their refolding function [249-251]. 
Several heat shock proteins can be found in mitochondria, 
namely the classic Hsps Hsp60, mtHsp70 (mortallin), 
mtHsp90 (TRAP-1) and Hsp78 and small Hsps Hsp10, 
Hsp27, αB-crystallin, Hsp22, mtHsp40 [251-255]. 
It is no surprise that some Hsps are known to directly in-
teract with Aβ, namely Hsp70 and small Hsps; Hsp27 
(HSPB1), αB-crystallin (HSPB5), Hsp22 (HSPB8) and 
Hsp20 (HSPB6), because the handling of misfolded proteins 
is part of their natural role [249, 256-258]. More interest-
ingly, all of these Hsps are also proposed to be localized 
within mitochondria. 
Generally, it seems that Hsps are protective against Aβ 
toxicity in AD. The interaction of Hsps with Aβ was shown 
to decrease Aβ toxicity through its sequestration, affecting 
its trafficking, aggregation, clearance and fibril formation 
[249, 251, 257]. Moreover, a similar mechanism of action 
could occur in the processing of other pathological proteins 
involved in AD development, e.g. tau-protein and APP [250, 
259, 260]. However, it remains to be elucidated, whether 
these interactions take place inside the mitochondria and 
play a significant role in the processing of mitochondrial Aβ. 
Many Hsp90 and several Hsp70, Hsp40 and Hsp27 in-
hibitors were developed primarily for cancer treatment [261-
263], and surprisingly the inhibitors of both Hsp90 and 
Hsp70 proved to be potentially useful for AD treatment. In-
hibition of Hsp90 promotes the proteasomal degradation of 
tau and also activates heat shock factor-1 (HSF-1) to induce 
Hsp70 and Hsp40 production as well as other chaperone 
production, which in turn, promotes the disaggregation and 
degradation of the disease associated proteins Aβ and tau 
[264, 265]. Many Hsp90 inhibitors/HSF-1 activators were 
found to exert neuroprotective properties in AD models or to 
ameliorate Aβ toxicity. From these compounds the most 
promising ones (to be used as AD therapeutics) seem to be 
the analogues of the coumarin antibiotic novobiocin (e.g. 
A4; Fig. 21; Table 15) targeting the C-terminal of Hsp90 
[266, 267]. Inhibition of Hsp70 also promotes proteasomal 
degradation of tau via a mechanism of action distinct from 
Hsp90 inhibition. The suitability of this approach was con-
firmed using the selective Hsp70 inhibitor MKT-077 or its 
BBB-permeable analogue YM-08 (Fig. 21; Table 15) [265, 
268, 269]. Additionally, YC-1 (Fig. 21; Table 15) an activa-
tor of guanylyl cyclase, was shown to decrease Aβ toxicity 
via the induction of Hsp70 expression and activity. However, 
its precise mechanism of action needs to be clarified [270]. 
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Fig. (21). Structure of selected Hsp inhibitors. 
HS-1-ASSOCIATED PROTEIN X-1 (HAX-1) 
HS-1-associated protein X-1 (HAX-1) comprises a fam-
ily of ubiquitously expressed proteins that have been impli-
cated in a wide range of biological functions and particularly 
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in the regulation of programmed cell death. At the subcellu-
lar level, HAX-1 is predominantly localized in the mito-
chondria, and to a lesser extent in the ER and nuclear mem-
brane [271, 272]. In a yeast two-hybrid screen HAX-1 was 
identified as a binding partner of Aβ [209], however, there is 
no other evidence currently available connecting HAX-1 
with AD or Aβ pathophysiology. 
CONCLUSION 
Amyloid-β peptide is by its nature a very promiscuous 
fellow. As summarized in this review, about 20 Aβ-binding 
partners are currently known in the mitochondria alone, and 
this number is probably not definitive (Table 16). Hence, 
effects of elevated Aβ levels on mitochondria (and ultimately 
the whole organism) are likely to be a consequence of many 
different protein-peptide interactions. Regarding an AD 
treatment, the pharmacological targeting of a single A β-
binding partner will probably not be sufficient to cure the 
whole disease, but it could ameliorate some of the symptoms 
or at least slow down the disease progression. As presented 
in (Table 16), at least five such Aβ-binding partners (drug-
gability score ***) seem to be very rational drug targets for 
AD treatment, namely ABAD, CypD, γ -secretase, GAPDH 
and IDE. These proteins have all been successfully targeted 
in vivo using neurodegenerative animal models and a change 
in either their expression or their pharmacological modula-
tion resulted in a decrease of neurodegeneration symptoms. 
Table 16. Summary of Presented Proteins, Their Mitochondrial Localization, Evidence for the Direct Interaction With Aβ, Signifi-
cance of Their Role in AD Pathophysiology and Their Potential and Suitability As a Drug Target for AD Treatment. The 
Number of Stars Represents the Degree of Significance With *** Being the Highest Score, ** An Intermediate Score and * 
the Lowest Score 
Protein 
Localization in  
Mitochondria 
Evidence for Direct  
Interaction with Aβ 
Significance in AD  
Pathophysiology 
Potential As a Drug Target 
ABAD matrix *** *** *** 
CypD matrix, IMM *** *** *** 
ANT IMM ** ** ** 
VDAC OMM ** ** ** 
ETC - Complex I IMM ** ** * 
ETC - Complex IV IMM ** ** * 
ETC - Complex V IMM * ** * 
KGDHC IMM ** * * 
PDHC matrix ** * ** 
CK IMS * * * 
γ-secretase OMM *** *** *** 
NOS IMM ** ** ** 
PAD not specified ** ** ** 
Table 15. Predicted Physical-chemical Properties of Selected Hsp Inhibitors Compared to Optimal Properties for CNS Targeted 
Drugs [16, 17] 
H-bond	   ClogD	  
Compound	   Mw	  
acc./don.	  
PSA [Å2]	   ClogP ± SD	  
(pH 7.4)	  
CpKa ± SD	  
Optimal properties	   ≤400	   ≤7/≤3	   ≤60-70	   1-5	   0-3	   4-10	  
A4	   393.3	   9/3	   124	   -0.3	   -0.3	   12.2	  
YC-1	   304.34	   4/1	   51	   3.7	   3.7	   13.8	  
MKT-077	   396.55	   4/0	   78	   0.8	   0.8	   NA*	  
YM-08	   367.49	   4/0	   87	   4.1	   4.1	   NA*	  
* Not available. 
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(Table 16) contd…. 
Protein 
Localization in  
Mitochondria 
Evidence for Direct  
Interaction with Aβ 
Significance in AD  
Pathophysiology 
Potential As a Drug Target 
SOD1 IMS, matrix, OMM *** ** * 
Catalase matrix *** ** ** 
Drp-1 OMM ** ** ** 
GAPDH OMM *** *** *** 
HtrA2 IMS *** ** ** 
PreP matrix *** ** ** 
IDE not specified *** *** *** 
Hsps not specified *** ** ** 
HAX-1 not specified * * * 
 
ABBREVIATIONS 
ABAD = Amyloid-binding alcohol dehydrogenase 
ABAD-DP = ABAD-decoy peptide 
AD = Alzheimer's disease 
AICD = Amyloid precursor protein intracellular 
domain 
ALS = Amyotrophic lateral sclerosis 
ANT = Adenine nucleotide translocase 
APP = Amyloid precursor protein 
Aβ = Amyloid-β peptide 
BACE = β-secretase 
BBB = Blood-brain barrier 
BKA = Bongkrekic acid 
CAT = Carboxylatractyloside 
CK = Creatine kinase 
CsA = Cyclosporine A 
CypD = Cyclophilin D 
Drp1 = Dynamin-related protein 1 
ER = Endoplasmic reticulum 
ETC = Electron transport chain 
GAPDH = Glyceraldehyde-3-phosphate dehydro-
genase 
GSI = γ-secretase inhibitor 
GSM = γ-secretase modulator 
HAX-1 = HS-1-associated protein X-1 
HIG1 = Hypoxia-inducible gene 1 = domain mem-
ber 1A 
HSF-1 = Heat shock factor-1 
Hsp = Heat shock protein 
HtrA2 = High temperature requirement protease A2 
IDE = Insulin-degrading enzyme 
IMM = Inner mitochondrial membrane 
IMS = Intermembrane space 
KGDHC = α-ketoglutarate dehydrogenase complex 
MAO B = Monoamine oxidase B 
MOMP = Mitochondrial outer membrane permeabil-
ity 
mPT = Mitochondrial permeability transition 
MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri- 
dine 
mPTP = mPT pore 
NOS = Nitric oxide synthase 
OMM = Outer mitochondrial membrane 
PAD = Peptidylarginine deiminases 
PD = Parkinson's disease 
PDHC = Pyruvate dehydrogenase complex 
PDHK = Pyruvate dehydrogenase kinase 
PreP = Presequence protease 
PS = Presenilin 
ROS = Reactive oxygen species 
SDR = Short chain dehydrogenase reductase 
SfA = Sanglifehrin A 
SOD1 = Cu/Zn superoxide dismutase 
TIM = Translocase of the inner membrane 
TOM = Translocase of the outer membrane 
VDAC = Voltage-dependent anion channel 
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